指南与共识头颈部肿瘤放疗姑息放疗与转移瘤

头颈部SABR应用共识:多机构德尔菲研究结果

Defining the Role of SABR in Head and Neck Cancer: Results From a Multi-institutional Delphi Consensus.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2026-05-22

该研究通过三轮改良德尔菲法,邀请有头颈部SABR经验的放射肿瘤科医生对103条陈述进行共识评级。结果显示,56条(54.3%)达成共识,12条(11.7%)达成主要同意;共识支持再照射、不可切除肿瘤、第二原发及寡转移等场景,但术后SABR和首次治疗中的SABR推量未达成共识。

要点

  • 共识支持SABR用于再照射小孤立复发、不可切除肿瘤、已照射野内第二原发及未治疗患者寡转移。
  • 技术共识包括VMAT、2-3mm PTV边距、多模态影像及每日容积影像医师验证,不推荐预防性淋巴结照射。
  • 术后SABR(含切缘阳性或结外 extension)及首次治疗SABR推量未达成共识。

核心结论

  • 该多机构德尔菲研究提供了反映当前头颈部SABR实践状态的专家建议,并确定了未来研究重点。

研究设计与样本

  • 2021年7月至2023年1月进行三轮改良德尔菲法,邀请有头颈部SABR经验的放射肿瘤科医生参与。
  • 第一轮为开放式问题,第二、三轮对103条涉及适应证、禁忌证、计划、剂量分割、毒性缓解、系统治疗整合和随访的陈述进行同意度评级。

主要发现

  • 103条陈述中,56条(54.3%)达成共识,12条(11.7%)达成主要同意。
  • 共识支持SABR用于再照射小孤立复发、不可切除肿瘤或已照射野内第二原发,以及未治疗患者的寡转移病灶。
  • 局部姑息治疗及临床试验中不适合标准分割的患者使用SABR也达成共识。
  • 术后SABR(包括切缘阳性或结外 extension)及首次治疗中的SABR推量未达成共识。
  • 系统治疗整合未达成共识。

关键数值与推荐

  • 共识定义为≥75%同意,主要同意为65%至74%。
  • 技术共识支持容积调强弧形治疗、2至3 mm的计划靶区边距、多模态影像(薄层CT、MRI和PET/CT)及每日容积影像医师验证。
  • 不鼓励临床靶区外扩,不推荐预防性淋巴结照射。
  • 支持隔日分割及邻近关键结构处剂量降低。
  • 共识强调对关键毒性进行咨询,并支持SABR后2至3个月影像检查。

临床怎么用

  • 可将SABR用于再照射小孤立复发、不可切除肿瘤、已照射野内第二原发及未治疗患者寡转移。
  • 技术实施推荐VMAT、2-3mm PTV边距、多模态影像及每日容积影像医师验证,避免临床靶区外扩和预防性淋巴结照射。
  • 可考虑隔日分割及邻近关键结构处剂量降低,并在SABR后2至3个月进行影像随访。
  • 术后SABR及首次治疗SABR推量缺乏共识,系统治疗整合亦无共识,需个体化决策。

局限性

  • 术后SABR、首次治疗SABR推量及系统治疗整合等关键领域未达成共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of SABR in head and neck cancer remains uncertain. Historically, it has been used mainly for reirradiation, and its application in other clinical scenarios has expanded with recent advances. OBJECTIVE: To develop an international expert consensus on indications, technical parameters, and clinical application of head and neck SABR using a modified Delphi process. METHODS: A three-round modified Delphi process was conducted between July 2021 and January 2023. Radiation oncologists with experience in head and neck SABR were invited to participate. Round 1 consisted of open-ended questions. Rounds 2 and 3 involved rating agreement with 103 statements addressing indications, contraindications, planning, dose and fractionation, toxicity mitigation, systemic therapy integration, and follow-up. Consensus was defined as ≥75% agreement, and major agreement as 65% to 74%. RESULTS: Seventeen of 26 invited experts (65.4%) completed all rounds, with representation from North America, Europe, and Asia-Oceania. Of the 103 statements, 56 (54.3%) reached consensus, and 12 (11.7%) achieved major agreement. Consensus supported SABR for reirradiation of small isolated recurrences, unresectable tumors, or second primaries in previously irradiated fields, and oligometastatic lesions in untreated patients. Use in local palliation and in patients unfit for standard fractionation within a clinical trial also met consensus. No consensus was reached for postoperative SABR, including its use for positive margins or extranodal extension, nor for SABR boost in first-course treatment. Technically, consensus favored volumetric modulated arc therapy, tight planning target volume margins of 2 to 3 mm, multimodality imaging (thin-slice computed tomography, magnetic resonance imaging, and positron emission tomography/computed tomography), and daily volumetric imaging with physician verification. Clinical target volume expansion was discouraged, and elective nodal irradiation was not recommended. Every-other-day fractionation and dose reduction near critical structures were endorsed. Consensus emphasized counseling on key toxicities and supported imaging at 2 to 3 months post-SABR. No consensus was reached on systemic therapy integration. CONCLUSION: This multi-institutional Delphi study provides expert-derived recommendations reflecting the current state of head and neck SABR practice and identifies priorities for future research.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Petit C, Phan J, Ng SP, et al. Defining the Role of SABR in Head and Neck Cancer: Results From a Multi-institutional Delphi Consensus. Int J Radiat Oncol Biol Phys. 2026. PMID: 42176868. doi:10.1016/j.ijrobp.2026.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。